Expression of proteoglycan versican in in situ breast lesions: Relations between stromal changes, histotype, and invasion

Pathology Research and Practice

Volumn 207, Issue 2, 2011, Pages 97-103

  Canavese, G ^a   Candelaresi, G ^a   Castellano, I ^a   Mano, M P ^a  

^a AOU San Giovanni Battista   (Italy)

Author keywords

Breast; In situ carcinoma; Versican

Indexed keywords

PROTEOGLYCAN; VERSICAN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER STAGING; CARCINOMA IN SITU; CONNECTIVE TISSUE; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MYOFIBROBLAST; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOGLYCAN SYNTHESIS; STROMA; TISSUE STRUCTURE; TISSUE TYPES;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; STROMAL CELLS; VERSICANS;

EID: 79551584745     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2010.10.009     Document Type: Article

References (22)

1. Wu Y.J., La Pierre D.P., Wu J., Yee A.J., Yang B.B. The interaction of versican with its binding partners. Cell Res. 2005, 15(July (7)):483-494. (Review).
2. Wight T.N. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr. Opin. Cell Biol. 2002, 14(October (5)):617-623. (Review).
3. Bode-Lesniewska B., Dours-Zimmermann M.T., Odermatt B.F., Briner J., Heitz P.U., Zimmermann D.R. Distribution of the large aggregating proteoglycan versican in adult human tissues. J. Histochem. Cytochem. 1996, 44(April (4)):303-312.
4. Howeedy A.A., Virtanen I., Laitinen L., Gould N.S., Koukoulis G.K., Gould V.E. Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Lab. Invest. 1990, 63(December (6)):798-806.
5. Koukoulis G.K., Howeedy A.A., Korhonen M., Virtanen I., Gould V.E. Distribution of tenascin, cellular fibronectins and integrins in the normal, hyperplastic and neoplastic breast. J. Submicrosc. Cytol. Pathol. 1993, 25(April (2)):285-295. (Review).
6. Adams M., Jones J.L., Walker R.A., Pringle J.H., Bell S.C. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Res. 2002, 62(June (11)):3289-3297.
7. Nara Y., Kato Y., Torii Y., Tsuji Y., Nakagaki S., Goto S., Isobe H., Nakashima N., Takeuchi J. Immunohistochemical localization of extracellular matrix components in human breast tumours with special reference to PG-M/versican. Histochem. J. 1997, 29(January (1)):21-30.
8. Ricciardelli C., Brooks J.H., Suwiwat S., Sakko A.J., Mayne K., Raymond W.A., Seshadri R., LeBaron R.G., Horsfall D.J. Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin. Cancer Res. 2002, 8(April (4)):1054-1060.
9. Suwiwat S., Ricciardelli C., Tammi R., Tammi M., Auvinen P., Kosma V.M., LeBaron R.G., Raymond W.A., Tilley W.D., Horsfall D.J. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin. Cancer Res. 2004, 10(April (7)):2491-2498.
10. Yee A.J., Akens M., Yang B.L., Finkelstein J., Zheng P.S., Deng Z., Yang B. The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res. 2007, 9(4):R47.
11. Kischel P., Waltregny D., Dumont B., Turtoi A., Greffe Y., Kirsch S., De Pauw E., Castronovo V. Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int. J. Cancer 2010, 126(February (3)):640-650.
12. Jahkola T., Toivonen T., Nordling S, von Smitten K, Virtanen I Expression of tenascin-C in intraductal carcinoma of human breast: relationship to invasion. Eur. J. Cancer 1998, 34(October (11)):1687-1692.
13. Iskaros B.E., Sison C.P., Hajdu S.I. Tenascin patterns of expression in duct carcinoma in situ of the breast. Ann. Clin. Lab. Sci. 2000, July (30)(3):266-271.
14. Chauhan H., Abraham A., Phillips J.R., Pringle J.H., Walker R.A., Jones J.L. There is more than one kind of myofibroblast: analysis of CD34 expression in benign, in situ, and invasive breast lesions. J. Clin. Pathol. 2003, 56(April (4)):271-276.
15. Barth P.J., Ebrahimsade S., Ramaswamy A., Moll R. CD34+ fibrocytes in invasive ductal carcinoma, ductal carcinoma in situ, and benign breast lesions. Virchows Arch. 2002, 440(March (3)):298-303. (Epub 2001 November 22).
16. Pavlakis K., Messini I., Vrekoussis T., Yiannou P., Keramopoullos D., Louvrou N., Liakakos T., Stathopoulos E.N. The assessment of angiogenesis and fibroblastic stromagenesis in hyperplastic and pre-invasive breast lesions. BMC Cancer 2008, 2(April (8)):88.
17. Shekhar M.P., Pauley R., Heppner G. Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast. Breast Cancer Res. 2003, 5(3):130-135. (Epub 2003 February 20).
18. Kass L., Erler J.T., Dembo M., Weaver V.M. Mammary epithelial cell: influence of extracellular matrix composition and organization during development and tumorigenesis. Int. J. Biochem. Cell Biol. 2007, 39(11):1987-1994. (Epub 2007 July 19).
19. Pontier S.M., Muller W.J. Integrins in mammary-stem-cell biology and breast-cancer progression - a role in cancer stem cells?. J. Cell Sci. 2009, 122(January (Pt 2)):207-214.
20. Li C.I., Malone K.E., Saltzman B.S., Daling J.R. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. Cancer 2006, 106(May (10)):2104-2112.
21. Wärnberg F., Yuen J., Holmberg L. Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet 2000, 355(February (9205)):724-725.
22. Rawal R., Lorenzo Bermejo J., Hemminki K. Risk of subsequent invasive breast carcinoma after in situ breast carcinoma in a population covered by national mammographic screening. Br. J. Cancer 2005, 92(January (1)):162-166.